Document is current
Any future updates will be listed below
-
Authors
Bugge, Christoffer https://orcid.org/0000-0002-0766-2870
Engebretsen, Ingrid https://orcid.org/0000-0001-9608-6731
Kristiansen, Ivar Sønbø https://orcid.org/0000-0002-5389-6010
Sæther, Erik Magnus
Lindberg-Schager, Ingrid https://orcid.org/0000-0002-6549-6065
Arneberg, Fredrik
Gilhus, Nils Erik
-
Funding
Funding for this research was provided by:
UCB Pharma AS
- License Information
-
More Information
Article History
Received: 25 September 2024
Revised: 24 October 2024
Accepted: 26 October 2024
First Online: 12 December 2024
Declarations
:
: Christoffer Bugge, Ingrid Engebretsen, Ivar Sønbø Kristiansen, and Erik Magnus Sæther are affiliated with Oslo Economics and have all completed consultancy assignments for several pharmaceutical companies in recent years. Ingrid Lindberg-Schager and Fredrik Arneberg work at UCB Pharma. Nils Erik Gilhus has received financial support from UCB, Argenx, Janssen, Merck, Roche, Alexion and Immunovant.
